Bank of Montreal Can Has $1.94 Million Position in Structure Therapeutics Inc. (NASDAQ:GPCR)

Bank of Montreal Can boosted its holdings in Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 71.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 46,502 shares of the company's stock after buying an additional 19,408 shares during the period. Bank of Montreal Can owned approximately 0.08% of Structure Therapeutics worth $1,941,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in the business. Sandia Investment Management LP bought a new stake in shares of Structure Therapeutics during the second quarter valued at approximately $39,000. Assetmark Inc. increased its position in shares of Structure Therapeutics by 120.0% during the third quarter. Assetmark Inc. now owns 1,318 shares of the company's stock valued at $58,000 after purchasing an additional 719 shares during the period. Quarry LP bought a new stake in shares of Structure Therapeutics during the second quarter valued at approximately $79,000. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Structure Therapeutics by 60.1% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,784 shares of the company's stock valued at $158,000 after purchasing an additional 1,420 shares during the period. Finally, Dearborn Partners LLC bought a new stake in shares of Structure Therapeutics during the third quarter valued at approximately $202,000. 91.78% of the stock is owned by institutional investors.

Structure Therapeutics Stock Performance

Structure Therapeutics stock traded up $2.11 on Friday, reaching $33.35. The company's stock had a trading volume of 829,578 shares, compared to its average volume of 785,204. The company has a market cap of $1.91 billion, a price-to-earnings ratio of -44.50 and a beta of -3.41. The business's fifty day moving average price is $37.46 and its 200 day moving average price is $39.32. Structure Therapeutics Inc. has a twelve month low of $26.61 and a twelve month high of $62.85.

Wall Street Analyst Weigh In

Several brokerages recently commented on GPCR. HC Wainwright began coverage on Structure Therapeutics in a research note on Wednesday. They issued a "buy" rating and a $80.00 price target on the stock. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $65.00 price target on shares of Structure Therapeutics in a research note on Monday, September 23rd. Morgan Stanley began coverage on Structure Therapeutics in a research note on Monday, September 23rd. They issued an "overweight" rating and a $118.00 price target on the stock. Finally, JMP Securities decreased their price target on Structure Therapeutics from $91.00 to $86.00 and set a "market outperform" rating on the stock in a research note on Friday, August 9th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average price target of $85.67.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.